Chapter title |
Bosutinib: A Potent Second-Generation Tyrosine Kinase Inhibitor
|
---|---|
Chapter number | 4 |
Book title |
Small Molecules in Hematology
|
Published in |
Recent results in cancer research Fortschritte der Krebsforschung Progrès dans les recherches sur le cancer, January 2018
|
DOI | 10.1007/978-3-319-91439-8_4 |
Pubmed ID | |
Book ISBNs |
978-3-31-991438-1, 978-3-31-991439-8
|
Authors |
Isfort, Susanne, Crysandt, Martina, Gezer, Deniz, Koschmieder, Steffen, Brümmendorf, Tim H., Wolf, Dominik, Susanne Isfort, Martina Crysandt, Deniz Gezer, Steffen Koschmieder, Tim H. Brümmendorf, Dominik Wolf |
Abstract |
Bosutinib is one of the five tyrosine kinase inhibitors which are currently approved for the treatment of chronic myeloid leukemia. By its dual inhibition of Src and ABL kinase and also targeting further kinases, it creates a unique target portfolio which also explains its unique side effect profile. The approval of bosutinib in 2013 made the drug available for patients previously treated with one or more tyrosine kinase inhibitor(s) and for whom imatinib, nilotinib, and dasatinib are not considered appropriate treatment options. As initially the first-line clinical trial comparing bosutinib with imatinib in CML patients in chronic phase did not reach its primary endpoint and therefore the product was not licensed for first-line therapy, a second first-line trial, the so-called BFORE study, was performed and just recently the promising results have been published predicting a quick expansion of the existing label. In comparison with the other approved TKIs, bosutinib harbors a distinct side effect profile with only very few cardiovascular and thromboembolic events and minimal long-term safety issues with most adverse events happening during the first months of treatment. On the other hand, gastrointestinal side effects are very common (e.g., diarrhea rates in more than 80% of the patients) with bosutinib surprising some of the investigators during the early clinical trials evaluating bosutinib. Until then, several approaches have been used to face this problem resulting in extensive supportive efforts (such as early loperamid treatment) as well as new trials testing alternative dosing strategies with early dose adjustment schedules. This article reports preclinical and clinical data available for bosutinib both in hematologic diseases such as CML or ALL and solid tumours as well as other diseases and envisions future perspectives including additional patient groups in which bosutinib might be of clinical benefit. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 23 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 4 | 17% |
Researcher | 3 | 13% |
Student > Postgraduate | 2 | 9% |
Student > Bachelor | 2 | 9% |
Student > Ph. D. Student | 1 | 4% |
Other | 2 | 9% |
Unknown | 9 | 39% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 5 | 22% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 13% |
Biochemistry, Genetics and Molecular Biology | 3 | 13% |
Immunology and Microbiology | 1 | 4% |
Neuroscience | 1 | 4% |
Other | 2 | 9% |
Unknown | 8 | 35% |